ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck Returns One Drug, Licenses Others

by Ann M. Thayer
March 3, 2014 | APPEARED IN VOLUME 92, ISSUE 9

Merck & Co. has returned rights to ridaforolimus, a small-molecule cancer drug candidate it had licensed from Ariad Pharmaceuticals. The companies entered a $564 million development deal in 2010, and Merck filed for approval in the U.S. and elsewhere the next year. However, it withdrew a European application in late 2012 after U.S. regulators said additional clinical trials were required before approval. As of the end of 2012, Merck had paid Ariad $75 million in licensing and milestone fees. In a new deal, Merck is licensing undisclosed small molecules from Copenhagen-based Nuevolution. The agreement is the second between the firms but the first preclinical compound licensing deal for Nuevolution.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment